Alpha-L-iduronidase precursor
Alpha-L-iduronidase precursor Brand names, Alpha-L-iduronidase precursor Analogs
Alpha-L-iduronidase precursor Brand Names Mixture
- No information avaliable
Alpha-L-iduronidase precursor Chemical_Formula
C3160H4848N898O881S12
Alpha-L-iduronidase precursor RX_link
http://www.rxlist.com/cgi/generic3/aldurazyme.htm
Alpha-L-iduronidase precursor fda sheet
Alpha-L-iduronidase precursor msds (material safety sheet)
Alpha-L-iduronidase precursor Synthesis Reference
No information avaliable
Alpha-L-iduronidase precursor Molecular Weight
69899.4
Alpha-L-iduronidase precursor Melting Point
Mandelli J, Wajner A, Pires R, Giugliani R, Coelho JC. Detection of mucopolysaccharidosis type I heterozygotes on the basis of the biochemical properties of plasma alpha-L-iduronidase. Clin Chim Acta. 2001 Oct;312(1-2):81-6.
Alpha-L-iduronidase precursor H2O Solubility
No information avaliable
Alpha-L-iduronidase precursor State
Liquid
Alpha-L-iduronidase precursor LogP
-0.300
Alpha-L-iduronidase precursor Dosage Forms
Solution (IV infusion)
Alpha-L-iduronidase precursor Indication
For the treatment of mucopolysaccharidosis
Alpha-L-iduronidase precursor Pharmacology
Laronidase is used to treat mucopolysaccharide storage disorders (specifically mucopolysaccharidosis 1 or Hurlers syndrome) caused by deficiencies of alpha-L-iduronidase. Reduced or absent a-L-iduronidase activity results in the accumulation of the GAG substrates, dermatan sulfate and heparan sulfate, throughout the body and leads to widespread cellular, tissue, and organ dysfunction.
Alpha-L-iduronidase precursor Absorption
No information avaliable
Alpha-L-iduronidase precursor side effects and Toxicity
No information avaliable
Alpha-L-iduronidase precursor Patient Information
No information avaliable
Alpha-L-iduronidase precursor Organisms Affected
Humans and other mammals
